cbdMD annual gross margin
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
cbdMD's gross margin was 62.36% for fiscal 2025.
View full cbdMD company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-09-30 | 62.36% | +2.15 pp |
| 2024 | 2024-09-30 | 60.21% | +0.43 pp |
| 2023 | 2023-09-30 | 59.78% | −0.39 pp |
| 2022 | 2022-09-30 | 60.17% | −3.18 pp |
| 2021 | 2021-09-30 | 63.35% | +0.39 pp |
| 2020 | 2020-09-30 | 62.96% | +1.59 pp |
| 2019 | 2019-09-30 | 61.37% | −15.97 pp |
| 2018 | 2018-09-30 | 77.34% | +7.63 pp |
| 2017 | 2017-09-30 | 69.71% | +49.38 pp |
| 2016 | 2016-09-30 | 20.34% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q3 2026 | 2026-06-30 | 54.69% | −6.76 pp |
| Q2 2026 | 2026-03-31 | 57.75% | −4.56 pp |
| Q1 2026 | 2025-12-31 | 59.82% | −6.68 pp |
| Q4 2025 | 2025-09-30 | 58.83% | +4.97 pp |
| Q3 2025 | 2025-06-30 | 61.45% | −4.33 pp |
| Q2 2025 | 2025-03-31 | 62.31% | +8.73 pp |
| Q1 2025 | 2024-12-31 | 66.50% | +0.32 pp |
| Q4 2024 | 2024-09-30 | 53.85% | −7.70 pp |
| Q3 2024 | 2024-06-30 | 65.78% | +6.28 pp |
| Q2 2024 | 2024-03-31 | 53.58% | −7.40 pp |
| Q1 2024 | 2023-12-31 | 66.18% | +9.01 pp |
| Q4 2023 | 2023-09-30 | 61.55% | +2.75 pp |
| Q3 2023 | 2023-06-30 | 59.50% | −7.40 pp |
| Q2 2023 | 2023-03-31 | 60.98% | −3.77 pp |
| Q1 2023 | 2022-12-31 | 57.17% | +6.51 pp |
| Q4 2022 | 2022-09-30 | 58.80% | +10.35 pp |
| Q3 2022 | 2022-06-30 | 66.90% | +3.57 pp |
| Q2 2022 | 2022-03-31 | 64.75% | −4.37 pp |
| Q1 2022 | 2021-12-31 | 50.66% | −21.51 pp |
| Q4 2021 | 2021-09-30 | 48.45% | −5.96 pp |
| Q3 2021 | 2021-06-30 | 63.33% | −1.43 pp |
| Q2 2021 | 2021-03-31 | 69.12% | −1.81 pp |
| Q1 2021 | 2020-12-31 | 72.18% | +8.64 pp |
| Q4 2020 | 2020-09-30 | 54.41% | −2.35 pp |
| Q3 2020 | 2020-06-30 | 64.76% | +1.35 pp |
| Q2 2020 | 2020-03-31 | 70.93% | +4.90 pp |
| Q1 2020 | 2019-12-31 | 63.54% | −0.93 pp |
| Q4 2019 | 2019-09-30 | 56.76% | −8.64 pp |
| Q3 2019 | 2019-06-30 | 63.41% | −19.59 pp |
| Q2 2019 | 2019-03-31 | 66.03% | −0.80 pp |
| Q1 2019 | 2018-12-31 | 64.46% | +13.82 pp |
| Q3 2018 | 2018-06-30 | 65.40% | −19.97 pp |
| Q2 2018 | 2018-03-31 | 83.00% | +11.28 pp |
| Q1 2018 | 2017-12-31 | 66.83% | +48.27 pp |
| Q4 2017 | 2017-09-30 | 50.64% | — |
| Q3 2017 | 2017-06-30 | 85.37% | — |
| Q2 2017 | 2017-03-31 | 71.72% | — |
| Q1 2017 | 2016-12-31 | 18.56% | — |
Over the last five reported fiscal years, cbdMD's gross margin decreased from 62.96% to 62.36%, a change of −0.59 percentage points. The latest reported quarter, Q3 2026, shows 54.69%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review cbdMD filings at SEC.gov ↗